Mostafa Atri1, Zheng Zhang2, Farrokh Dehdashti3, Susanna I Lee4, Shamshad Ali5, Helga Marques2, Wui-Jin Koh6, Kathleen Moore7, Lisa Landrum7, Jae Weon Kim8, Paul DiSilvestro9, Eric Eisenhauer10, Frederick Schnell11, Michael Gold12. 1. University Health Network, Canada. Electronic address: mostafa.atri@uhn.ca. 2. Brown University, United States. 3. Washington University School of Medicine, United States. 4. Massachusetts General Hospital, United States. 5. Roswell Park Cancer Institute, United States. 6. Washington University, United States. 7. University of Oklahoma Health Science Center, United States. 8. Seoul National University College of Medicine, Republic of Korea. 9. Stony Brook, United States. 10. University of Cincinnati, United States. 11. Central Georgia Cancer Care, United States. 12. Tulsa Cancer Institute, United States.
Abstract
OBJECTIVE: To assess if FDG PET combined with diagnostic CT improves diagnostic CT accuracy to detect lymph node (LN) metastasis in advanced cervical cancer. METHODS: A prospective HIPAA compliant ACRIN/GOG multicenter trial was conducted. Patients underwent concurrent diagnostic contrast-enhanced CT (DCT) and PET and pelvic/abdominal lymphadenectomy. Seven independent blinded readers reviewed PET-DCT and DCT one-month apart. Reference standard was surgically removed LN pathology. Accuracy values were calculated at participant level, correlating abdominal (right and left para-aortic/common iliac) and pelvic (right and left external iliac/obturator) LN regions with pathology, respecting laterality. Reader average sensitivities/specificities of PET-DCT vs. DCT were compared with generalized linear mixed models, and AUCs with Obuchowski's method. RESULTS: One hundred fifty-three patients had PET-DCT and pathology. Forty-three of 153 patients had metastasis to abdominal LNs. Sample size calculation required review of the first 40 abdominal positive and 40 randomly selected abdominal negative studies. Patients were 24 to 74years (48.9±10.6) old. Mean sensitivities of PET-DCT/DCT for detection of LN metastasis in abdomen were 0.50 (CI: 0.44, 0.56) and 0.42 (CI: 0.36, 0.48) (p=0.052) and in pelvis 0.83 (CI: 0.78, 0.87) and 0.79 (CI: 0.73, 0.83) (p=0.15). Corresponding specificities were 0.85 (CI: 0.80, 0.89) and 0.89 (CI: 0.84, 0.92) (p=0.21) and 0.63 (CI: 0.54, 0.70) and 0.62 (CI: 0.53, 0.69) (p=0.83). Mean AUC values were 0.70 (CI: 0.61, 0.79) and 0.68 (CI: 0.59, 0.77) (p=0.43) and 0.80 (CI: 0.71, 0.88) and 0.76 (CI: 0.67, 0.85) (p=0.21) respectively. CONCLUSION: Addition of PET to DCT resulted in statistically borderline increase in sensitivity to detect LN metastasis in abdomen in advanced cervical cancer.
OBJECTIVE: To assess if FDG PET combined with diagnostic CT improves diagnostic CT accuracy to detect lymph node (LN) metastasis in advanced cervical cancer. METHODS: A prospective HIPAA compliant ACRIN/GOG multicenter trial was conducted. Patients underwent concurrent diagnostic contrast-enhanced CT (DCT) and PET and pelvic/abdominal lymphadenectomy. Seven independent blinded readers reviewed PET-DCT and DCT one-month apart. Reference standard was surgically removed LN pathology. Accuracy values were calculated at participant level, correlating abdominal (right and left para-aortic/common iliac) and pelvic (right and left external iliac/obturator) LN regions with pathology, respecting laterality. Reader average sensitivities/specificities of PET-DCT vs. DCT were compared with generalized linear mixed models, and AUCs with Obuchowski's method. RESULTS: One hundred fifty-three patients had PET-DCT and pathology. Forty-three of 153 patients had metastasis to abdominal LNs. Sample size calculation required review of the first 40 abdominal positive and 40 randomly selected abdominal negative studies. Patients were 24 to 74years (48.9±10.6) old. Mean sensitivities of PET-DCT/DCT for detection of LN metastasis in abdomen were 0.50 (CI: 0.44, 0.56) and 0.42 (CI: 0.36, 0.48) (p=0.052) and in pelvis 0.83 (CI: 0.78, 0.87) and 0.79 (CI: 0.73, 0.83) (p=0.15). Corresponding specificities were 0.85 (CI: 0.80, 0.89) and 0.89 (CI: 0.84, 0.92) (p=0.21) and 0.63 (CI: 0.54, 0.70) and 0.62 (CI: 0.53, 0.69) (p=0.83). Mean AUC values were 0.70 (CI: 0.61, 0.79) and 0.68 (CI: 0.59, 0.77) (p=0.43) and 0.80 (CI: 0.71, 0.88) and 0.76 (CI: 0.67, 0.85) (p=0.21) respectively. CONCLUSION: Addition of PET to DCT resulted in statistically borderline increase in sensitivity to detect LN metastasis in abdomen in advanced cervical cancer.
Authors: J C Horiot; J Pigneux; H Pourquier; S Schraub; E Achille; R Keiling; P Combes; R Rozan; C Vrousos; N Daly Journal: Int J Radiat Oncol Biol Phys Date: 1988-04 Impact factor: 7.038
Authors: Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; David G Mutch; Matthew A Powell; Perry W Grigsby Journal: J Clin Oncol Date: 2010-03-22 Impact factor: 44.544
Authors: Bruce E Hillner; Barry A Siegel; Anthony F Shields; Dawei Liu; Ilana F Gareen; Ed Hunt; R Edward Coleman Journal: J Nucl Med Date: 2008-11-07 Impact factor: 10.057
Authors: Michael S Gee; Mostafa Atri; Andriy I Bandos; Robert S Mannel; Michael A Gold; Susanna I Lee Journal: Radiology Date: 2017-11-29 Impact factor: 11.105
Authors: Jocelyn S Chapman; I-Chow Hsu; Pamela N Peters; William E Pierson; Lee-May Chen; Antonio C Westphalen Journal: Abdom Radiol (NY) Date: 2020-07-08
Authors: Alexander J Lin; Jason D Wright; Farrokh Dehdashti; Barry A Siegel; Stephanie Markovina; Julie Schwarz; Premal H Thaker; David G Mutch; Matthew A Powell; Perry W Grigsby Journal: Int J Gynecol Cancer Date: 2019-08-30 Impact factor: 3.437
Authors: Ester P Olthof; Maaike A van der Aa; Judit A Adam; Lukas J A Stalpers; Hans H B Wenzel; Jacobus van der Velden; Constantijne H Mom Journal: Int J Clin Oncol Date: 2021-07-09 Impact factor: 3.402